Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jay`s weekly, two hour VoiceAmerica radio show, "Turning Hard Times into Good Times" will be broadcast Tuesday, January 17th at 3:00PM Eastern Time and 12:00 Noon Pacific Time and can be located by clicking here or at www.voiceamerica.com/Show/1501. It is also archived, and can be heard on www.jaytaylormedia.com.
Boys And Girls Load the Truck mark my words!!! PZG will be best gold/silver stock to own in 2012 2nd to none!!! What does PZG Albert Freidberg largest shareholder and Paramount Gold and Silver Corp CEO Chris Crupi know? Well lets just say they know they have what Coeur D Alene and Gold Corp wants!!! What price will they pay ?
Thanks Richdag AIS should fly to $4 dollars with positive LibiGel data looking for it any day next 2 weeks!!!
Maybe SPRL will run again like last year .003 yesssssssssssssss
JBJD is this really Sam Hyams and Strat Petroleum SPRL wow!!! moving on air very very thin!!!!
DNDN The positive news just keeps flowing in and will continue for quite some time !!! Ride this wave!!!
SPRL NEWS Does CEO Sam Hyamms confirm this news to be true ?
Time for the Winter Run Spike in Natural Gas Prices im buying here!!! I have to agree with DEJ posted message taken from Brown48 STOCKHOUSE MB 11/16/2011 GREAT TIMES AHEAD!!! The stock price of Dejour is about to explode. Revenues of 8 million in 2011 will turn into 18 million in 2012 and these are net to Dejour. Woodrush is about to push through 1000 boe net to the company and Gibson Gulch is a 40% return even @ current natural gas prices. With a land portfolio of 22 million dollars @ cost and now that all cylinders are firing both analysts predictions of $1 + should materialize rather quickly. Big reward ahead for those who are currently buying in.
Mr Miller great analyst update on DNDN, current Buy Rating and 12 month price target is $14
NEOM.....NEOM....NEOM....Fire Works to begin soon!!!
NeoMedia Technologies, Inc. (OTC BB: NEOM.OB), the global leader in mobile barcode scanning solutions, today announced that industry expert Peter Mannetti has been appointed to the NeoMedia Board of Directors. Mr. Mannetti, with more than 20 years’ experience in the telecommunications and electronics industries, will be a welcome addition to the NeoMedia Board, working with the company’s leadership and other Board members to further NeoMedia’s position in the mobile marketing ecosystem. Mr. Mannetti’s appointment will become effective October 1, 2011.
More on Press Releases
Amsterdam Molecular Therapeutics Receives Orphan Designation In The European Union For Hemophilia B Gene TherapySYSWIN Inc. Announces Third Quarter 2011 Unaudited Financial ResultsSeoul To Host World's First Online Mayoral Inauguration CeremonyPioneer Exploration Inc. - Corporate UpdatePromaxBDA Announces Winners At 2011 Sports Media Marketing AwardsU.S. Census Bureau Daily Feature For November 16America's State Of Mind: New Report Finds Americans Increasingly Turn To Medications To Ease Their Mental Woes; Women Lead The TrendBoycotts And The Bottom LineAll-New Ford Escape: Smarter Utility Vehicle Saves Customers Fuel, Money; New Technologies To Make Owners' Lives EasierMirus Bio And Reinnervate Collaborate To Introduce The 3D Transfection System: Enabling Transfection Of Cells In 3D CultureMarket Activity
NeoMedia Technologies Inc.| NEOM Mr. Mannetti is a Managing Partner at iSherpa Capital, LLC, joining the firm in 2001. Mr. Mannetti previously founded and built Qwest Wireless from the ground up into a $1 billion company with over one million subscribers. As the Chief Executive Officer of the firm, he won national and international awards for his leadership in developing innovative wireless products. Prior to joining Qwest, Mr. Mannetti was a Vice President at BellSouth Mobile Data and held various management positions during his 18-year tenure at General Electric. Mr. Mannetti sits on a number of Boards and Advisory Boards and is also very active in the education and non-profit sectors.
“Peter is an exceptional business leader and we are delighted that he is joining the NeoMedia Board of Directors. Peter’s track record speaks for itself, having successfully built Qwest Wireless and winning several prestigious awards along the way. I have known Peter for a number of years and look forward to working with him more closely as we leverage his vast international management and financial experience to help expedite the company’s growth,” said Laura Marriott, CEO and Board Chairperson of NeoMedia.
“The mobile marketing space is an exciting place to be right now as brands and marketers look to harness the power and exponential growth of mobile in their campaigns,” said Peter Mannetti. “I look forward to working with Laura and the rest of the Board in contributing to the company’s sustained success.”
Hi all anyone know why NEOM is trading heavily past few days ?
Interesting article i read Saturday, November 12, 2011. Here it is!!!
Dendreon's Provenge: Some On The Street Doth Protest Too Much
Forgive me if I begin with a (mis)quote:
“The [Street] doth protest too much methinks”
(Queen, in Hamlet (Quarto 2) 3.2; with apologies to William Shakespeare)
I am, of course, alluding to the constant barrage of negative articles, in print and on the internet, attacking both Dendreon (DNDN) and its lead immunotherapeutic treatment Provenge. Former White House speech writer William Safire would have labeled the authors of these articles the ‘nattering nabobs of negativism.’
Hardly a day goes by without someone attacking Dendreon’s management for pulling its revenue guidance early in August, or Provenge for any variety of reasons, most of them specious or overcome by events.
The most recent example was an article published on the internet that cited various sources who took issue with Provenge because:
the “time and inconvenience of extracting white blood cell” (I posit that six sittings in a one-month period is not onerous when you compare that to the daily regime of taking other medications, which I will get to below)
“reimbursement issues” (mostly resolved, as far as I am aware, now that CMS has issued the Q-code (.pdf) in July, 2011, providing all Medicare payers with uniform guidance, and Dendreon has provide community and academic providers with a comprehensive Reimbursement and Billing Guide (.pdf). Note: That there still may be lingering problems involving certain community providers is not disputed. Based on my own experience with doctors in private practice (don’! t ask!), problems can be expected, given the unique billing services each employs as well as the varied experiences and capabilities of these services. Providers who use internal staff members to augment their back office staff may encounter a greater number of problems with reimbursement at all levels, owing to the complexities of the private and Medicare/Medicaid (federal and state) reimbursement systems.)
“The vaccine has to be made for each individual patient.” (Well, yes…Provenge is uniquely personal.)
The article published on the Internet also failed to note there is evidence that Provenge has an effect on time to disease-related pain. In an abstract presented at the ASCO annual meeting this year, the pooled results of the randomized asymptomatic sub-group from the three Phase III trials in mCRPC showed a trend to delay in disease-related pain (HR .80, adjusted for baseline predictive factors). Furthermore at 12 months, 39% percent of Provenge arm versus 19% of control arm were pain free. Although not ‘stat sig,’ possibly because of the small sample size, it is an indication that Provenge could have an impact on other important clinical outcomes besides survival.
Notwithstanding the fact that, in my opinion, the Internet article cited above was a paean to Johnson & Johnson’s (JNJ) Zytiga, it strikes me odd that week after week, month after month, “the Street doth protest too much mee thinks.”
What’s going on here?
Before I answer that question, let’s examine some facts. Zytiga (abiraterone acetate), according to JNJ, the manufacturer, in combination with prednisone, is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel. More specifically, although Zytiga has shown about a four-month median survival advantage in mCRPC, it is in a patient population that has FAILED docetaxel (Taxotere®; ! this is from the ‘COU-AA-301’ trial). Its survival benefit has not yet been proven (the ‘COU-AA-302’ trial is currently underway) in the asymptomatic/minimally symptomatic mCRPC setting for which Provenge is indicated. Indeed, in this specific space, the National Comprehensive Cancer Network, or NCCN, has given Provenge a category 1 rating, the highest evidence level recommendation based upon its three Phase III clinical trials.
By contrast, and in Provenge’s ‘space’— asymptomatic/minimally symptomatic mCRPC setting— Zytiga has a category 2B rating, the second lowest rating, based upon small single arm Phase II trials. ("Abiraterone acetate can also be considered for men with metastatic CRPC who are not candidates for chemotherapy. Use of abiraterone acetate in patients who have not received prior docetaxel is based on single arm Phase II clinical trial data. A Phase III placebo-controlled trial in the pre-docetaxel setting has been completed; results are not yet available. Until those results are available, docetaxel remains the standard of care for CRPC for patients refractory to secondary hormone therapy who are candidates for chemotherapy."(NCCN; log-in required)
This isn’t to imply that the results of Zytiga’s pivotal Phase III, randomized, placebo-controlled, multicenter study in the post-docetaxel setting were not a major advance in the care of PCa sufferers. Indeed, at the pre-specified interim analysis, treatment with Zytiga in combination with prednisone resulted in a 35 percent reduction in the risk of death (14.8 months vs. 10.9 months [hazard ratio (HR) = 0.646; 95 percent CI: 0.543, 0.768; p<0.0001]) and a 3.9 month difference in median survival compared to placebo plus prednisone. In an updated analysis, results were consistent with those from the interim analysis with a 4.6 month difference between the two arms in median survival (15.8 months vs. 11.2 months [HR = 0.74]).
Admirable. And ind! eed, JNJ , has much to crow about.
So, let’s talk cost. Zytiga costs $5,000 a month, and is usually given for eight cycles. Some argue that these two factors alone make it a preferred treatment.
But wait a minute. What about prior authorization? Here’s what Medicare (.pdf) has to say (among other things):
Prior Authorization Group: ZYTIGA
Drug(s): ZYTIGA (abiraterone acetate tablets)
Covered Uses:
All FDA-approved indications not otherwise excluded from Part D.
Required Medical Information:
Symptoms and biopsy confirming diagnosis of metastatic castration-resistant prostate cancer
Documented progression on docetaxel treatment.
Prescriber Restrictions: Oncologist.
Other Criteria:
Use in combination with prednisone.
Failure of docetaxel treatment or significant adverse effect.
Exclusion Criteria: Zytiga will not be covered in the following situations:
Frequency/dose greater than FDA approved labeling
Development of severe hepatotoxicity.
Uncontrolled hypertension.
Uncorrected hypokalemia.
ALT greater than 5 X ULN during treatment of Zytiga
AST greater than 5 X ULN during treatment of Zytiga
Total bilirubin greater than 3 X ULN
Prior ketoconazole treatment for prostate cancer AND history of adrenal gland or pituitary disorders.
And what about side effects? Comparing side effects on the ‘ability to go out and do what patients normally would do’, the Zytiga prescribing information (.pdf) lists as the most common adverse reaction as ‘ joint swelling or discomfort, hypokalemia, edema, muscle discomfort, hot flush, diarrhea, urinary tract infection, cough, hypertension, arrhythmia, urinary frequency, nocturia, dyspepsia, and upper respiratory tract infection.’ This doesn’t even mention, of cou! rse, pot ential liver toxicity, which requires continual liver function testing. By contrast, the most common side effects of Provenge (.pdf) are ‘chills, fatigue, fever, back pain, nausea, joint ache, and headache.’ basically flu-like symptoms that typically resolve themselves within a few days.
Finally, many overstate the convenience of Zytiga relative to Provenge. Zytiga dosing is not just ‘taking a pill.’ It is taking three pills every day (Zytiga once, and prednisone, a powerful steroid, twice) for eight months based on MEDIAN duration of treatment in the ‘301’ trial. As far as ‘ability to eat and drink,’ Zytiga must be taken on an empty stomach, with no food for at least two hours prior to and for at least one hour after taking Zytiga—every day for eight months. By contrast, Provenge requires a 3-4 hour leukapheresis to harvest white blood cells and upon being processed into Provenge, about an hour to re-infuse. This occurs three times over the course of a month and then, the entire course of treatment is completed.
Zytiga and Provenge each have their place in the PCa treatment spectrum. Instead of trying to promote one drug while minimizing another using canards, fabrications, and rumors, the message should be that men with late stage prostate cancer have a number of treatment options available that did not exist as little as two years ago, with more drugs on the horizon.
Another important message should be that the use of different drugs is not an either-or proposition. In many cases, and specifically in the case of Zytiga and Provenge, the use of one does NOT preclude the use of the other. This is related to the fact that the mechanisms of action, or MOAs, are different. Thus, in the case with Zytiga and Provenge, optimal sequencing may extend survival even further.
Here’s what the Journal of Clinical Oncology recently said about that subject:
[T]he practical dilemma of the appropriate! sequenc e of use of the two new noncytotoxic agents (sipuleucel-T [Provenge] and abiraterone) is being addressed by trials that are under development. For now, given the broader window of applicability of abiraterone and the longer time required to develop an immune response with sipuleucel-T, if both agents are to be used, it seems reasonable to administer sipuleucel-T first with Abiraterone after additional disease progression. Biomarkers to help define the optimal use of immunotherapy are needed.
So, what’s my ‘take’ regarding all the ‘noise’ in the press and on the Internet that appears intended to smear Dendreon and Provenge? Simply this. The incessant, almost shrill attacks against the company and its lead treatment speak, I think, not only to competitive pressures within the pharmaceutical industry, but also, to efforts that are intended to thwart the introduction of twenty first century treatments based on harnessing the body’s own immune system. To this end, Dendreon’s competitors and ‘antagonists’ alike have enlisted a cadre of analysts, ‘journalists,’ and so-called ‘experts’ willing and, unfortunately, able to spread fear, uncertainty, and doubt among both patients and investors regarding the company’s immunotherapeutic treatment for end stage prostate cancer. Fortunately, it is doctors who will be looking out for the best interests of their patients, and not journalists or analysts that will recommend and prescribe Provenge.
The availability of Provenge heralds the delivery of a new age of immunological weapons in our armamentarium of treatments against cancer. It is the fulfillment of an age old promise. After all, wasn’t a Nobel Prize for Medicine just awarded to Ralph Steinman, who discovered so-called dendritic cells in 1973. These cells regulate the activity of other cells. Steinman called them the conductor of the immune system. As many authors noted (here and here, for example! ), one e xample of this type of technology is the drug for incurable prostate cancer called sipuleucel-T (brand name is Provenge).
Investors, of course, risk only their money when they invest in the companies that populate the biotech universe. Sufferers of prostate cancer and other serious illnesses who have run out of options, and who fail to see through the smoke screen of disinformation as they search for data on potential treatments, risk paying with the quality of their lives, if not their lives themselves, should they are unable to gather, often from the popular literature, unbiased information that can inform their medical decisions.
As for the Dendreon’s goal of signing 700 infusion sites* by the end of calendar year 2011, the current site count, determined using Dendreon's Provenge site stood at 680 as of September 30, 2011. States with the highest number of infusion sites at that time were California (60 sites), Illinois (57), Florida (41), Texas (40), and North Carolina (34).
From a technical standpoint (insert the ‘Symbol’ DNDN where indicated on the Web page), DNDN currently is hovering just below $9. Bearish sentiment reigns across the markets worldwide following credit rating cuts of Spain and Italy. The stock is still coming off its oversold conditions, and the Daily MACD line is climbing. On a Weekly basis, the stock is oversold, and the Weekly MACD line is showing signs of bottoming.
*As this article was just about to go the publisher, I learned that the number of infusion sites has climbed to 700, a 16% increase from the number authorized to deliver the treatment at the beginning of August, 2011.
Disclosure: I am long DNDN and will not change my position with 72 hours of the time this article is published.
Dendreon DNDN is a buy up to $10. Great investment IMO for 2012. My target is $40 in 2012 You heard it here first!!!!
Charly Travers, Motley Fool Million Dollar Portfolio analyst: I'm calling Dendreon (Nasdaq: DNDN ) as the comeback stock of 2012. A confluence of factors ranging from management's loss of credibility, slashed Provenge sales guidance, and a slower-than-expected sales ramp has sent this former highflier stock crashing back to Earth. As a one-of-a-kind product for treating prostate cancer, Provenge holds a lot of value, and I expect Dendreon's shares to bounce back.
Mark my words!!! Dennis M. Fenton will do for Dendreon what he did for Amgen. THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 1, 2007--Amgen (NASDAQ: AMGN) today announced that Dennis Fenton, executive vice president of Operations, has elected to retire at the end of 2007, after 25 years with the company. Fenton, 55, is one of Amgen's longest-tenured staff members, joining the company during its first 12 months. A research scientist by training, Fenton worked in and led virtually every part of Amgen over the years including Research, Process Development, Sales and Marketing, Engineering and Manufacturing.
"Dennis will be deeply missed by all of us who have had the pleasure to work with him over the years. He has been one of the greatest champions of the Amgen values and a true ambassador of our heritage," said Amgen Chairman and CEO Kevin Sharer. "As head of Operations, Dennis helped build the most reliable, efficient and skilled biotechnology manufacturing operation in the world. For that achievement, among many others, we are eternally grateful."
Dennis M. Fenton Leadership of his caliber is what we have been anxiously looking for. This is the right place at the right time to add Dennis M. Fenton to this BOD. Its Crunch Time for Dendreon!!!
Gold should resign. With the right leadership this stock could have been a $100 stock by now IMO. His Report Card gets a big F in my books!!!
IMO DNDN is a steal under $7 for my $40 target in 2012.
I agree 100% DNDN will do fine this 4th quater and 2012 will be a banner year for DNDN IMO. Taken from yahoo MB nice post.New Accounts Become Consistent Prescribers 17 minutes ago Mitch during Conference Call-
"Many of the key questions we’ve heard from the investor community are related to the underlying demand for PROVENGE what we are seeing is that sales from old account have continued at a consistent rates this year. In addition new accounts opened for approximately 90 days have become consistent prescribers of PROVENGE. Our long-term goal is increased utilization in all of these accounts. However, it does suggest that once physicians become comfortable with PROVENGE it is becoming an integral part of their practice."
BIG HUMP TO GET OVER- then nothing like it- Lowest Side Effect Profile- I'd take it if I needed it- So Would You
Ill be buying DNDN @ $5.50 to $6.00 all day tommorow. This is way oversold though it may sell off another 15% to 20% more with all the panic and then it will be the best buy in our life time IMO.
BYD CO (NASDAQ:BYDDY) Uptrend Smart Scan Chart Analysis is showing some near term weakness. However, this market remains in the confines of a longer term Uptrend with tight money management stops.
Based on a pre-defined weighted trend formula for chart analysis, BYDDY scored +70 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
+10 Last Hour Close Above 5 Hour Moving Average
+15 New 3 Day High on Monday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending October 15th
-30 New 3 Month Low in September
+70 Total Score
Open High Low BYDDY Price Change
3.69 3.81 3.69 3.79 +0.15
Streaming Chart
BIOCRYST PHARMACEUTICALS (NASDAQ:BCRX) Uptrend Smart Scan Chart Analysis is showing some near term weakness. However, this market remains in the confines of a longer term Uptrend with tight money management stops.
Based on a pre-defined weighted trend formula for chart analysis, BCRX scored +70 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
+10 Last Hour Close Above 5 Hour Moving Average
+15 New 3 Day High on Monday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending October 29th
-30 New 3 Month Low in August
+70 Total Score
Open High Low BCRX Price Change
2.88 3.05 2.87 3.02 +0.15
DENDREON (NASDAQ:DNDN) Uptrend
Smart Scan Chart Analysis is showing some near term weakness. However, this market remains in the confines of a longer term Uptrend with tight money management stops.
Based on a pre-defined weighted trend formula for chart analysis, DNDN scored +70 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
+10 Last Hour Close Above 5 Hour Moving Average
+15 New 3 Day High on Monday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending October 29th
-30 New 3 Month Low in October
+70 Total Score
Edit Your Symbol List Get Advanced Analysis
PATRIOT COAL (NYSE:PCX) Uptrend
Smart Scan Chart Analysis is showing some near term weakness. However, this market remains in the confines of a longer term Uptrend with tight money management stops.
Based on a pre-defined weighted trend formula for chart analysis, PCX scored +70 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
+10 Last Hour Close Above 5 Hour Moving Average
+15 New 3 Day High on Monday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending October 29th
-30 New 3 Month Low in October
+70 Total Score
Open High Low PCX Price Change
10.11 10.98 10.03 10.93 +0.97
Hello StockMarketKid! Just recently bought BRAV @.0046 200K shares to start. Looks like were just getting started. IMO if we get this same volume tommorow were going to fly!!!! Go $BRAV!!!!!!!
sellers are going to regret if this becomes the next enkg!!!
.0014 lots a lovin to do yet
REV-Guidance 10/19/2011 will get us to pennyland!!!
buy 200 K @.0046 slap the ask and we fly today and tommorow thru year end Merry Christmas
Antares Pharma (AMEX: AIS ) Anturol Gel Treatment for overactive bladder 12/8/2011. Any guesses on stock price if we get FDA approval in just 3 short weeks no matter if the market is up or down ?
GSX my pick for tommorow and the next 10 days!
Excited About GSX This Mega Trend will Catapult GSX to the Moon!!! http://www.cngnow.com/news/default.aspx
Pronew GSX is my pick for now thru this coming winter!!! Looking for at least a 5 to 10 bagger!!!
about gasco operations newsroom investor relations governance contact
NYSE Amex: GSX
Overview
Management
Directors
ABOUT GASCO ENERGY | Overview
Denver-based Gasco Energy, Inc. (NYSE Amex: GSX) is a natural gas and oil exploitation and development company focused on natural-gas-rich prospects in the Rocky Mountain area of the United States, specifically in Utah’s Uinta Basin. Additional exploration leasehold is located in California and Nevada.
The Company’s principal business strategy is to enhance stockholder value by using technologies new to a specific area to generate and develop high-potential exploitation resources in this area. Gasco’s principal business is the acquisition of leasehold interests in petroleum and natural gas rights, either directly or indirectly, and the exploitation and development of properties subject to these leases.
Gasco currently focuses its efforts in the Riverbend Project located in the Uinta Basin of northeastern Utah, targeting the Wasatch, Mesaverde and Blackhawk, Mancos and Dakota/Morrison gas bearing formations and the oil-prone Green River Formation. As of December 31, 2010, Gasco held interests in 282,326 gross acres (228,724 net acres) located in Utah, Wyoming, California and Nevada. As of December 31, 2010, we held an interest in 133 gross producing wells (79.4 wells, net to our interest) and three gross shut-in wells located on these properties.
The Rockies represent the largest untapped, drillable potential for natural gas supply in North America. The Potential Gas Committee (PGC) estimates ultimate recovery of total gas reserves in the Rockies at 230 trillion cubic feet, excluding coalbed methane. The PGC estimates the greatest potential for non-associated natural gas in the Rocky Mountain region is concentrated in southwestern and south-central Wyoming, adjacent northwestern Colorado and northeastern Utah. This region includes the Uinta, Piceance and Greater Green River Basins.
Gasco Energy,Inc. 8 Inverness Dr. Suite 100, Englewood, Colorado 80112 • Phone: (303) 483-0044 Fax: (303) 483-0011
Pronew Congrat on new board this should be fun!
BYD CO (NASDAQ:BYDDY) Uptrend Smart Scan Chart Analysis is showing some near term weakness. However, this market remains in the confines of a longer term Uptrend with tight money management stops.
Based on a pre-defined weighted trend formula for chart analysis, BYDDY scored +70 on a scale from -100 (strong downtrend) to +100 (strong uptrend):
+10 Last Hour Close Above 5 Hour Moving Average
+15 New 3 Day High on Thursday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, Week Ending October 15th
-30 New 3 Month Low in September
+70 Total Score
Open High Low BYDDY Price Change
3.70 3.86 3.66 3.86 +0.44
Streaming Chart
SURFKAST This One Has Been Pumped Up Hard Watching! Do You Follow CAMS, Looking For Explosive Run Next Week, Maybe Monday !!! Recent Post Exciting!!! LOL. Look at the time and sales, trades for the day. Notice when the pps ran up in the first 1 1/2 hours. Notice when the time between trades stalled. Notice when the bashers started posting on the board, after lunch. Notice when the bid squatters lowered their bids. Notice when the large single trade changed the buy sell ratio from positive to negative. Notice the negative paint job at the close at .0006.
The stock traded like a low float should, ran up fast and down the same way. It happened to a lot of stocks today, just look at the top 15 or twenty highest volume otcbb or pink stock today. It was Friday.
Call it whatever you want, but it is normal in the pennies and if it has never happened to you or to a stock you were watching, it will, and often.
A few days back this stock had closed at .0010, opened there the following day, dropped to .0006, then shot up to .0017 and closed at .0012. That is what penny stocks do and low floaters do it daily.
So use your charts and follow the trends that are longer than a few minutes, hours, or days so you are not always panicked. When I look at a stock like this I notice the MACD(12,26,9) and weekly indicators more than the daily or hourly. So if you look at the MACD for this one you will see why it had all the volume to push it up this morning. NO NEWS EITHER. NO PUMP AND DUMP. Just the chart and the normal behavior of Friday trading. Get in, get a gain, and get out for the weekend. Simple.
Two posters here confirmed and posted the emails from the transfer agent yesterday confirming the float at 133mil. One of them confirmed it had not changed even today. So if the float is 133mil and the MACD is touching and ready for a positive crossover, I like this a lot. It may take off Monday or a few days latter, but it is highly likely that it will take off soon as this mornings trading showed.
When that positive crossover happens and the MACD goes from 0.00 , which is where it is right now, to +0.01 you will see what you saw this morning only it will hold and continue for days.
You had 3 red days in a row after today and that is normal after a recent run up to .0017 and now yo are back down to where that last run started, .0006 again. If she pushes up Monday from here you will have a double bottom and that will be very good so look for it Monday.
I hope this helps you. I am still watching the charts and I still like what I have seen. Everyone that bought this today should be fine when she goes up and that MACD line crosses positive. MAYBE MONDAY
DNDN UPtrend Beginning!!! Time To Buy Buy Buy !!!
ZLCS Been In A Strong Downtrend! Looking For Uptrend! Will Management Get Their Act Together! This Company Has Great Potential With The Right Leadership!!!
Boys And Girls This Company Has The Goods!!! Uptrend Beginning Again! Ready To Make A Shit Load Of Money!!!